Jimmy Vanhove serves as the CEO of Viralgen and TAAV, global contract development and manufacturing organizations (CDMOs) specializing in adeno-associated virus (AAV) gene therapy. Both companies are wholly owned subsidiaries of AskBio & Bayer. Operating across three facilities in Spain and employing over 450 professionals, the company offers comprehensive development and manufacturing services, supporting projects from early-stage development through clinical and commercial production.

Prior to joining Viralgen in 2021, Jimmy held leadership roles in manufacturing, strategy consulting, and operational transformation with organizations such as GSK Vaccines, Bayer, and Roland Berger. He holds master’s degrees in Bioscience Engineering from KU Leuven and General Management from Vlerick Business School, along with executive training at IESE and IMD. His journey has fueled his commitment to building organizations that innovate, inspire, and push the boundaries of Science and Technology - delivering hope to patients and families worldwide.